[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648686":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental 18F-grazy-02 PET\u002FCT imaging","EXPERIMENTAL","The purpose of the study is to evaluate the safety and early monitoring performance of 18F-grazy-02 for immunotherapy.",[13],"Drug: 18F-grazy-02",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","18F-grazy-02","18F-grazy-02 PET\u002FCT: after intravenous injection of 2.96-3.7 MBq\u002Fkg body weight of quality-controlled 18F-grazy-02 , a Total-body PET\u002FCT uEXPLORER scanner will be applied.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Linyu Zhang","CONTACT","+86010-82805175","zhanglinyu1@pku.edu.cn",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Nan Li","Study Director","100648686","phase-1-18f-grazy-02-petct-of-granzyme-b-expression-for-monitoring-immunotherapy-100648686",false,"NCT07724535","18F-grazy-02 PET\u002FCT of Granzyme B Expression for Monitoring Immunotherapy","18F-grazy-02 PET\u002FCT of Granzyme B Expression for Monitoring Immunotherapy in Patients With Lymphoma or Solid Tumors","Inclusion Criteria:\n\n1. 18-75 years old;\n2. ECOG score 0 or 1 point;\n3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET\u002FCT imaging for tumor diagnosis or staging.\n\nExclusion Criteria:\n\n1. Pregnant or nursing;\n2. Severe hepatic or renal dysfunction;\n3. Low WBC (less than 3 x 10\\^9\u002FL);\n4. Unable to comply with the PET\u002FCT imaging procedures.",true,"ALL","18 Years","75 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61,62],"PHASE1","PHASE2","This is an open-label PET\u002FCT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.",[65],"Cancer","2026-07-29",{"date":68,"type":69},"2026-07-31","ACTUAL",{"date":71,"type":69},"2026-06-24",{"date":73,"type":58},"2028-12-31",{"name":5,"class":6},1]